Online Survey 2010
Survey II Living with Lupus: Career / Work Situation

The response of the 2009’s survey was clear: Lupus has been a life changing experience with the most highly significant affect on career.
A surprising statement, but yet not at all that big of surprise when you think about it. 
Lupus is most often diagnosed when the woman is up to 45 years of age. This means the time of your life, when you study to find your field of expertise and/or are in the midst of establishing a family. Career change.

But how and perhaps why?

We needed to investigate this further and prepared a new survey: with the specific aim to check whether having lupus means career change and how. We have been fortunate to be able to combine the parts of the survey with validated questionnaires on Fatigue, Work Impact and Lupus Quality of Life.

It is the first time all these aspects are combined.
Nevertheless, it is the first time an on-line survey addresses any person in Europe with lupus to give the individual reply to the situation of impact of lupus to career.

The survey was in five languages – English, French, German, Spanish and Italian:

The Clinical Advisory Group for the survey includes Professor Matthias Schneider, Professor David Isenberg and Professor Caroline Gordon from the LUPUS EUROPE Medical Advisory Panel.

Kirsten Lerstrøm is the Project Leader from LUPUS EUROPE working closely with the Trustees and the contacts of the five member countries providing the language translation.

The abstract “Impact of systemic lupus erythematosus on patients’ employment, family relationships, and overall well-being” submitted to EULAR was accepted as poster presentation for EULAR 2010 in Rome.

The methodology of the survey was presented during the 9th International SLE Congress at Vancouver and at the LUPUS EUROPE Annual Convention in Budapest in September 2010.

During 2011, the results will be presented at key European scientific lupus events and in 2013, it was published under the name Lupus European Online – LEO, and is available online. Please click on the link to access the full article : http://rheumatology.oxfordjournals.org/content/early/2013/09/18/rheumatology.ket300.full

THE RESULTS

2188 responses in total

English version – 596 responses (97,6% with lupus)
German version – 638 responses (98,9% with lupus)
French version – 215 responses (94,1% with lupus)
Italian version – 405 responses (98,1% with lupus)
Spanish version – 334 responses (97,1% with lupus)

Responses from “Other” (countries) only 6,4%

An amazing result!

The survey has been presented at the key events 2011 – European Lupus Meeting in Porto April 6-9 and at EULAR Congress 2011, London, May 25-28, and presented as poster during the DGRh congress in Munich, Germany, from August 31 – September 3, 2011

ONLINE PUBLICATIONS

MediLexicon – May 27, 2011
Hospital Pharmacy Europe – May 27, 2011
MediLexicon – May 29, 2011

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

🌈 The right to health is a basic human right. Everyone must have access to the health services they need when & where they need them without 💶 hardship.

😔 30% of the global population is not able to access essential health services.

#StandWithScience #WorldHealthDay #WHD2026
... See MoreSee Less

🌈 The right to he

🚀 #LupusGPT & #EasyLupus are currently offline as we continue improving them.

🛠️You thought they couldn’t get better? We know they can, & we’re making it happen.

In the meantime, for reliable, multilingual lupus information👉 lupus100.org/

💜Thanks for your support!
... See MoreSee Less

🚀 #LupusGPT & #Ea

🎥 Did you miss our ELM 2026 Recap Webinar?

😃 Watch it now on our YouTube channel!

👉 Our Patient Advisory Network (PAN) members and volunteers share their key takeaways from the European Lupus Meeting 2026.

👉 Doctors and researchers explain, in a clear, short, and patient-friendly way, key messages from their talks.

🎯 Click the link below and discover the latest advances in lupus, explained directly by experts:

www.youtube.com/watch?v=Bw5Iptu-ZNc

More insights from #elm2026 coming soon. Stay tuned!
... See MoreSee Less

🎥 Did you miss ou

We are very proud to share that LupusGPT has now been published in The Lancet Rheumatology, one of the world’s leading medical journals in rheumatology.

For us, this is not only about a publication. It is about what LupusGPT stands for.

LupusGPT is free. It is patient-led. And it was built to help people living with lupus find reliable, accessible information in almost any language.

It began with a simple but important question: what could become possible if patients, clinicians, and digital experts truly worked together from the start?

That question was first opened up in a fishbowl discussion at the European Lupus Meeting 2024 on how the lupus community could get the best, but not the worst, out of AI. From there, LupusGPT was shaped through the care, intelligence, and effort of many people: volunteers, patient testers, clinicians testing across languages, people who gave feedback, and people already helping us share it with patients in clinics, organisations, and communities.

This publication matters because it shows that patient-led innovation belongs in the scientific world too. It shows that when patient voice is not added at the end, but built in from the start, something real can grow.

A heartfelt thank you to all authors: Zoe Karakikla-Mitsakou, Alain Cornet, Jeanette Andersen, Sarah Dyball, Cristiana Sieiro Santos, Daniel Guimarães de Oliveira, and Laurent Arnaud. Special thanks also to Daniel Guimarães de Oliveira for the thought, care, and belief he brought to this work, and to Professor Laurent Arnaud for his outstanding support, steadiness, and guidance.

And above all, thank you to everyone in the Lupus Europe community who keeps showing us why this matters.

LupusGPT. Free. Multilingual. Patient-led. And now part of the scientific record.

doi.org/10.1016/S2665-9913(25)00370-4

Read it for free now! You only need to register (registration is completely free and takes 1')
... See MoreSee Less

We are very proud to